Live WEU eligibility
Know the WEU route is open across all 27 — before you commit.
Change #6 of 10 — RA / Pipeline Strategy
If a reference product exists, your WEU route is now closed.
Article 13 restricts WEU to substances where no reference product has been authorised or marketed anywhere in the EU. One authorisation in one Member State is enough to close it. Pipeline teams need an immediate eligibility check.
Art. 13 — Well-Established Use
EU-wide blockThe literature shortcut is closing
Well-Established Use lets you register on 10+ years of published literature — no new clinical trials.
Current — 2001/83/ECShortcut open
Blocked only in the one country that holds the reference product — file freely in the other 26.
New directiveShortcut closed
One reference product anywhere blocks WEU across all 27 — you must run a full or hybrid application with your own data.
Art. 13 turns a national block into an EU-wide one: once a reference product exists, the cheap literature route is gone and a far costlier application is the only way in.
Why this matters to your pipeline
One reference product anywhere in the EU closes the route
WEU is an efficient path for well-understood substances — Art. 13 tightens the eligibility gate significantly.
10yr
Minimum established use period unchanged — the new restriction is on reference product existence
SourceArt. 13, EU Pharmaceutical Directive 2026
1
Authorised or marketed reference product anywhere in EU-27 closes the WEU route
SourceArt. 13, EU Pharmaceutical Directive 2026
~15%
Estimated WEU applications in 2022–2024 that would not meet new Art. 13 criteria
SourceEMA product register analysis, 2024
What's actually changing
From broad eligibility to a narrow, defined route
Art. 13 tightens WEU further — and the new 'marketed' criterion introduces a monitoring obligation that didn't exist before.
Workbench
+ New TaskQuick Tasks/WEU eligibility — current vs new directive
We're two years into a WEU application. A competitor just received a national MA for the same substance in Slovenia. Are we still eligible?
RegIntel12:39
168.00s218 sources93% confidence2 warnings
2 warnings
Here's the obligation delta for WEU eligibility. The new EU Pharmaceutical Directive replaces Directive 2001/83/EC[1][2] — below is what changes, row by row.
Current vs. new directive4 rows
Change area
Current — 2001/83/EC
New directive — from ~mid-2028
Eligibility criterion
Current
WEU available where substance has 10+ years EU use with literature evidence. No exclusion based on reference product existence.
Reference product impact
Current
Reference products relevant to generic route but did not directly exclude WEU applications.
New directive
Authorised or marketed reference product anywhere in EU-27 directly excludes WEU. Full EU-wide reference product search required before committing.[5]
Alternative routes
Current
Applicants could choose WEU or generic/hybrid based on commercial strategy.
New directive
Where Art. 13 closes WEU, applicants must use generic, hybrid, or full application. Route migration planning is essential.[6]
⚠Dates reflect the political agreement text; final deadlines depend on entry into force and the transition period for each obligation.
Synthesised from 20 citations across 218 regulatory sources.
Book a 15-minute live walkthrough of the Workbench
Where teams get caught out
The missing layer
Most regulatory intelligence functions aren't set up to detect reference product events that invalidate a WEU submission mid-preparation.
EM
EMA product database (EPAR)
The public register
RA
RA consultancy advice
The one-time check
How Regunaut solves it
Five steps. Your WEU pipeline protected.
Each step maps a phase of WEU eligibility management — from initial screen through alternative route selection.
Checks EMA EPAR, 27 NCA registers and orphan registers — building a reference product map per substance with eligibility verdict: confirmed, ineligible, or at-risk.
- EU-wide product register search
- Reference product identification by substance and indication
- Eligibility verdict per substance
- Fixed combination assessment separate from components
Industry evidence
The WEU route is narrowing
As the EU product register fills with reference products, the pool of WEU-eligible substances shrinks.
8k+
Nationally authorised products not visible in EMA EPAR — the reference products most WEU applicants don't monitor
EMA/national CA analysis, 2024
12–18mo
Typical WEU dossier prep timeline — the window where an unexpected authorisation can invalidate investment
EMA WEU guidance, 2023
3×
Increase in nationally authorised registrations 2020–2024, accelerating reference product appearance
EFPIA generics report, 2024
“Companies that treat WEU eligibility as a point-in-time assessment rather than continuous monitoring will be caught out. A reference product in a small Member State can invalidate 18 months of preparation.”
Common questions
What teams are asking about WEU under Art. 13
Know your WEU eligibility position before you commit to the dossier
12–18 months of preparation is too much to risk on eligibility you haven't continuously monitored.
Screen your WEU pipeline
Get a WEU eligibility report across all 27 EU Member State registers.
Check WEU eligibilityMap your alternative routes
30-minute session reviewing generic, hybrid and full application options.
Book route strategy session